Corcept Therapeutics (CORT) Return on Capital Employed (2011 - 2026)

Corcept Therapeutics has disclosed Return on Capital Employed across 16 years of filings, most recently posting 1.21% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 1.21%, down 1704.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.21% (down 1704.0% YoY), and the FY2025 annual result was 6.66%, down 1654.0% from the prior year.
• Return on Capital Employed came in at 1.21% for Q1 2026 at Corcept Therapeutics, down from 6.75% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 33.86% in Q1 2022 to a low of 1.21% in Q1 2026.
• The 5-year median for Return on Capital Employed is 21.32% (2023), against an average of 19.58%.
• Across the five-year window, Return on Capital Employed soared 1274 bps in 2022 and tumbled 1704 bps in 2026, its largest moves.
• Corcept Therapeutics' Return on Capital Employed stood at 23.18% in 2022, then decreased by 8 bps to 21.32% in 2023, then decreased by 4 bps to 20.39% in 2024, then slumped by 67 bps to 6.75% in 2025, then sank by 118 bps to 1.21% in 2026.
• The last three Return on Capital Employed figures came in at 1.21% (Q1 2026), 6.75% (Q4 2025), and 10.24% (Q3 2025), per Business Quant data.